Lurbinectedin

Mechanism of Action

Lurbinectedin is an antineoplastic agent that belongs to the class of drugs called alkylating agents. It works by inducing DNA damage and blocking DNA repair, leading to cell death in cancer cells.

The mechanism of action of lurbinectedin involves the binding of the drug to DNA and the formation of covalent bonds with the DNA molecule. This binding leads to the formation of DNA adducts, which interfere with the normal functioning of DNA, including DNA replication and transcription.

Lurbinectedin specifically targets a type of RNA transcription called ""RNA polymerase II termination factor (RTF)"" which is overproduced in certain cancer cells. By inhibiting RTF, lurbinectedin causes the accumulation of RNA polymerase II on the DNA, leading to DNA damage and the eventual death of the cancer cell.

Indication

Lurbinectedin is a chemotherapy drug that is indicated for the treatment of advanced small cell lung cancer (SCLC) in adult patients with disease progression on or after platinum-based chemotherapy. It is also indicated for the treatment of adult patients with relapsed and refractory small cell lung cancer (RR-SCLC) who have received at least two prior lines of therapy.

It works by binding to and inhibiting the activity of an enzyme called RNA polymerase, which is important for the replication of cancer cells. This leads to the death of cancer cells and slows the progression of the disease.

Lurbinectedin should be administered under the supervision of a qualified healthcare provider experienced in the administration of cancer chemotherapy. It is important to carefully follow the dosing and administration instructions provided by your healthcare provider.

Dr. Reddy’sの専門知識・技術

ハイデラバード（インド）に本社を構えるDr. Reddy’s Laboratoriesは、世界的に有名な原薬（API）供給業者です。Dr. Reddy’sのAPIビジネスは米国、ヨーロッパ、ブラジル、南米、日本、中国、韓国、その他の新興市場において製薬会社の推奨パートナーとなっています。

Dr. Reddy’sのAPIビジネスは、ステロイド、ペプチド、複合長鎖分子、高薬理活性API（HPAPI /腫瘍学薬）など、複合APIの開発・製造において、30年以上にわたり高度な技術的実績を築き上げ、成長しています。この専門知識・技術は弊社の知的財産および規制関連業務の実績と共に、一貫して規制基準を満たし、それを超える優れた価値を生み出しています。Dr. Reddyの(-) API, R&D (研究開発)、IP、規制の高度な専門知識・技能の結果です。

顧客が真っ先に市場に参入するのに重要な要素は、機敏な供給網です。弊社は全施設を効率的に、そしてコストを最適化して稼働させ、品質と安全性、また、生産性の最新基準に従うことで、そうした供給網を実現させます。オフィスと工場の結びつきを強化し、ダイナミックな市場の変化に迅速に対応しています。そうした理由から、弊社は不足を解消して突発的な供給を満たすことができるのです。